Update shared on 25 Aug 2025
Fair value Decreased 12%GoHealth’s price target has been revised downward to $18.40, primarily reflecting reduced expectations for both future earnings multiples and revenue growth.
What's in the News
- GoHealth has formed a Transformation Committee with new board members to evaluate strategic opportunities, including acquisitions, securitizations, and capital structure options.
- The company is actively seeking acquisitions as part of efforts to create long-term stockholder value.
- Management highlights improved financial flexibility and strong lender support to pursue these initiatives.
Valuation Changes
Summary of Valuation Changes for GoHealth
- The Consensus Analyst Price Target has fallen from $19.60 to $18.40.
- The Future P/E for GoHealth has significantly fallen from 8.94x to 4.80x.
- The Consensus Revenue Growth forecasts for GoHealth has significantly fallen from 5.2% per annum to 3.8% per annum.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.